📊 INFOSYS Q2 FY27

• CC Revenue Growth: 1.2% QoQ vs 1.4% estimate

• USD Revenue: $5,145 Mn, up 1% QoQ vs $5,151 Mn estimate

• Total Contract Value (TCV): $5.2 Bn, up 44% QoQ

TORRENT PHARMACEUTICALS Q2FY27 :-

Revenue 4,979.00 Cr vs 3,302.00 Cr
(+50.79% YoY┃+1.18% QoQ)

EBITDA 1,666.00 Cr vs 1,083.00 Cr
(+53.83% YoY┃+0.12% QoQ)

EBITDA Margin 33.46% vs 32.80% YoY & 33.82% QoQ

PAT 534.00 Cr vs 591.00 Cr
(-9.64% YoY┃-5.65% QoQ)

EPS 14.05 vs 17.45 YoY & 14.87 QoQ

CUBEX TUBINGS Q2 FY27 (STANDALONE)

Net Profit: ₹5 Cr ↑163% YoY | ↑236% QoQ

Revenue: ₹83 Cr ↑13% YoY | ↑28% QoQ

EBITDA: ₹7 Cr ↑119% YoY | ↑407% QoQ

EBITDA Margin: 8.6% vs 4.4% YoY | 2.2% QoQ

TORRENT PHARMA Q2 FY27

Net Profit: ₹534 Cr ↓10% YoY | ↓6% QoQ

Revenue: ₹4,979 Cr ↑51% YoY | ↑1% QoQ

Operating Profit: ₹1,666 Cr ↑54% YoY | Flat QoQ

Operating Profit Margin: 33.5% vs 32.8% YoY | 33.8% QoQ

EPS: ₹14.05 ↓19% YoY | ↓6% QoQ

📊 INFOSYS Q2 FY27 – ACTUAL vs ESTIMATES

• Net Profit: ₹7,823 Cr vs ₹7,917 Cr — Miss by 1.19% 🔴

• Revenue: ₹49,244 Cr vs ₹49,194 Cr — Beat by 0.10% 🟢

• EBIT: ₹10,330 Cr vs ₹10,470 Cr — Miss by 1.34% 🔴

• EBIT Margin: 21.0% vs 21.3% estimated — Miss by 30 bps 🔴

Tata Motors Ltd – Q2 FY27 FINANCIAL RESULTS HIGHLIGHTS

Investor presentation for the quarter and half-year ended September 30, 2026:

- Standalone Revenue: INR 23900 Cr (up 42% YoY)

- Standalone EBITDA: INR 2800 Cr (up 31% YoY)

- Consolidated Revenue: INR 25300 Cr (up 36% YoY)

- Consolidated PBT (bei): INR 1800 Cr (up 423% YoY)

- Q2 Standalone Wholesales: 135.1K units (up 42% YoY)

- International Business Wholesales: 21.1K units (up 177% YoY)

Bank of India – Q2 FY27 FINANCIAL RESULTS HIGHLIGHTS

Unaudited (Reviewed) Standalone & Consolidated results for the quarter ended 30.09.2026:

- Net Profit: INR 3202 Cr (up 25% YoY)

- Global Business Mix: INR 1892601 Cr (up 21.13% YoY)

- Global Deposits: INR 1037530 Cr (up 21.59% YoY)

- Global Advances: INR 855071 Cr (up 20.58% YoY)

- Gross NPA: 1.60% (down from 2.54% YoY)

- Net NPA: 0.42% (down from 0.65% YoY)

BANK OF INDIA Q2 FY27 (STANDALONE)

Net Profit: ₹3,202 Cr ↑25.32% YoY | ↑4.37% QoQ

NII: ₹7,007 Cr ↑18.48% YoY | ↑2.55% QoQ

PPOP: ₹5,089 Cr ↑1% QoQ

Provisions: ₹797 Cr ↓17% QoQ

Gross NPA: 1.60% vs 1.81% QoQ

Net NPA: 0.42% vs 0.51% QoQ

JK TYRE & INDUSTRIES Q2 FY27 (CONS.)

Net Profit: ₹65.07 Cr ↓71.32% YoY | ↑47.58% QoQ

Revenue: ₹4,840.73 Cr ↑20.68% YoY | ↑22.67% QoQ

EBITDA: ₹333.91 Cr ↓35.96% YoY | ↑29.31% QoQ

EBITDA Margin: 6.90% vs 13.00% YoY | 6.54% QoQ

CRISIL Q2 FY26 (CONS.)

Net Profit: ₹204.54 Cr ↑5.92% YoY | ↓5.46% QoQ

Revenue: ₹1,095.16 Cr ↑20.18% YoY | ↑1.84% QoQ

EBITDA: ₹327.90 Cr ↑3.25% YoY | ↓1.32% QoQ

EBITDA Margin: 29.94% vs 34.85% YoY | 30.90% QoQ

SBI Funds Management Ltd – Q2 FY27 FINANCIAL RESULTS HIGHLIGHTS

Investor presentation for the quarter and half year ended September 30, 2026:

- MF QAAUM: INR 13,140 bn (15.0% market share)

- Passive QAAUM: INR 4,152 bn (27.4% market share)

- AIF QAAUM: INR 7437 Cr (up 27% YoY)

- SIP AUM: INR 2,070 bn (up 15% YoY)

- H1 FY27 Operating Income: INR 2336 Cr (up 12% YoY)

- H1 FY27 Operating Profit: INR 1797 Cr (up 11% YoY)

DR REDDY'S LABS Q2 FY27 (CONS.)

Net Profit: ₹913 Cr ↓31.71% YoY | ↑109.40% QoQ

Revenue: ₹8,698 Cr ↓1.47% YoY | ↑7.38% QoQ

EBITDA: ₹1,731 Cr ↓13.88% YoY | ↑101.28% QoQ

EBITDA Margin: 19.90% vs 22.77% YoY | 10.62% QoQ

Dr Reddys Laboratories Ltd – Q2FY27 FINANCIAL RESULTS UPDATE

Financial highlights for the quarter ended September 2026:

- Reported Revenues: INR 8671 Cr (up 1.5% YoY, 7% QoQ)

- EBITDA: INR 1783 Cr (up 24% YoY, 77% QoQ) at 20.6% margin

- PBT: INR 1228 Cr (up 33% YoY, 122% QoQ)

- PAT: INR 925 Cr (up 36% YoY, 109% QoQ)

- Net Cash surplus: INR 2502 Cr

- CDMO business (Aurigene): Surpassed $100 million in revenues for 12 months ended Sep'26

Dr Reddys Laboratories Ltd – APPOINTMENT OF SENIOR MANAGEMENT PERSONNEL

Appointment of new Head API and Services effective November 13, 2026:

- Mr. Akhil Ravi appointed as Head API and Services and Senior Management Personnel

- Mr. Akhil Ravi inducted as a Member of the Management Council

- He will continue to lead operations of Aurigene Pharmaceutical Services Ltd (wholly owned subsidiary)

- Mr. Akhil Ravi brings nearly 19 years of experience in strategy and commercial leadership

- He currently serves as CEO of Aurigene Pharmaceutical Services Ltd

GEOJIT FINANCIAL SERVICES Q2 FY27 (CONS.)

Net Profit: ₹16.28 Cr ↓30.62% YoY | ↓17.87% QoQ

Revenue: ₹165.82 Cr ↑2.56% YoY | ↑3.38% QoQ

EBITDA: ₹30.34 Cr ↓1.57% YoY | ↓4.41% QoQ

EBITDA Margin: 18.30% vs 19.06% YoY | 19.79% QoQ

RAMCO SYSTEMS Q2 FY27

Net Profit: ₹0.5 Cr ↓96% YoY | ↓20% QoQ

Revenue: ₹182 Cr ↑4% YoY | ↑5% QoQ

EBITDA: ₹26 Cr ↓34% YoY | ↑1% QoQ

EBITDA Margin: 14.2% vs 22.4% YoY | 14.7% QoQ

SHAKTI PUMPS Q2 FY27

Net Profit: ₹39 Cr ↓58% YoY | ↓25% QoQ

Revenue: ₹746 Cr ↑12% YoY | ↓13% QoQ

EBITDA: ₹64 Cr ↓53% YoY | ↓23% QoQ

EBITDA Margin: 8.6% vs 20.4% YoY | 9.6% QoQ

RUNWAL ENTERPRISES Q1 FY27 (CONS.)

Net Profit: ₹49.76 Cr ↓65.21% YoY | ₹62.02 Cr loss QoQ

Revenue: ₹338.16 Cr ↓24.21% YoY | ↑60.29% QoQ

EBITDA: ₹66.43 Cr ↓57.82% YoY | ₹39.74 Cr loss QoQ

EBITDA Margin: 19.65% vs 35.30% YoY | -18.84% QoQ

SHIVA CEMENT Q2 FY27

Net Loss: ₹22.85 Cr vs ₹32.73 Cr loss YoY | ₹21.35 Cr loss QoQ

Revenue: ₹112.70 Cr ↑37.25% YoY | ↓25.61% QoQ

EBITDA: ₹17.31 Cr ↑331.45% YoY | ↓7.19% QoQ

EBITDA Margin: 15.36% vs 4.89% YoY | 12.31% QoQ

SBI FUNDS MANAGEMENT Q2 FY27 (CONS.)

Net Profit: ₹7,012.44 Cr ↓5.99% YoY | ↓20.34% QoQ

Revenue: ₹11,926.72 Cr ↑8.91% YoY | ↑3.47% QoQ

EBITDA: ₹9,126.91 Cr ↑5.41% YoY | ↓1.11% QoQ

EBITDA Margin: 76.52% vs 79.07% YoY | 80.07% QoQ

TRUALT BIOENERGY Q2 FY27 (CONS.)

Net Profit: ₹34.99 Cr vs ₹37.94 Cr loss YoY | ↓40.96% QoQ

Revenue: ₹811.10 Cr ↑606.17% YoY | ↑29.39% QoQ

EBITDA: ₹101.16 Cr vs ₹4.55 Cr loss YoY | ↓23.80% QoQ

EBITDA Margin: 12.47% vs -3.96% YoY | 21.18% QoQ